Wonride M Tablet SR is a sustained-release oral antidiabetic medication containing a combination of Glimepiride (1mg) and Metformin (500mg). This formulation is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic control. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and reducing gastrointestinal side effects commonly associated with immediate-release metformin. Wonride M Tablet SR should be used as part of a comprehensive diabetes management plan, including diet modification, exercise, and regular blood glucose monitoring. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis or severe metabolic acidosis. Regular monitoring of blood glucose and periodic assessment of renal function are recommended during therapy. This combination therapy offers a synergistic approach to glycemic control, improving patient compliance through once-daily dosing.